Axsome Therapeutics Stock
Axsome Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Herriot Tabuteau
- Employees
- 1,346
- Market cap
- $8.2 B
- IPO
- 19/11/2015
Axsome Therapeutics, Inc. is a biopharmaceutical company within the healthcare sector dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders. Headquartered in New York City, USA, the company was established in 2012. Its primary focus is on the United States…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Axsome Therapeutics stock: price history
1D
-2.9%
1W
-6.7%
1M
-25.9%
6M
-16.9%
YTD
-14.0%
1Y
+25.7%
2Y
+74.7%
5Y
+291.9%
10Y
+2,055.6%
Next earnings date
Next earnings date
02/11/2026 (in 16 days)
Volatility around earnings
~27% stronger price swings than usual
Ask the agents about Axsome Therapeutics
Analyst assessment of Axsome Therapeutics
PRICE TARGET LOW
US$246.00
CONSENSUS
US$283.00
MEDIAN
US$275.00
PRICE TARGET HIGH
US$380.00
0
STRONG BUY
26
BUY
1
HOLD
0
SELL
0
STRONG SELL
27
TOTAL · Buy
As of: 08/10/2026
Axsome Therapeutics stock metrics
P/E
-41.9
P/B
97.15
EV/EBITDA
-46.16
RETURN ON EQUITY
-61.6%
NET MARGIN
-23.5%
DEBT/EQUITY
2.63
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
84.3%
FLOAT SHARES
44,182,629
AVG. DAILY VOLUME (30D)
803,255
Insider transactions (SEC)
Jacobson Mark L.
Jacobson Mark L.
TABUTEAU HERRIOT
TABUTEAU HERRIOT
TABUTEAU HERRIOT
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.9%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Axsome Therapeutics stock
What does Axsome Therapeutics do?
Axsome Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Herriot Tabuteau, the company employs around 1,346 people.
The IPO was on 19/11/2015; the stock trades on NASDAQ under the ticker AXSM.
What do analysts say about Axsome Therapeutics stock?
27 analysts rate the stock, the consensus is Buy (as of 08/10/2026).
The average price target is US$283.00, ranging from US$246.00 to US$380.00, with a median of US$275.00.
This is an external assessment, not a statement by Market Jury.
When does Axsome Therapeutics report next?
The next earnings date is 02/11/2026.
Around past earnings, price swings were roughly 27% stronger than usual.
Does Axsome Therapeutics pay a dividend?
No, Axsome Therapeutics currently does not pay a dividend.
Which stocks are comparable to Axsome Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Axsome Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Axsome Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.